TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is Trauma-Focused Cognitive Behavioral Therapy Effective in Reducing Post-traumatic Stress and Psychosocial Distress Among Sexually Exploited, War-affected Girls in the Democratic Republic of Congo.
Brief Summary: To date, no RCT has examined the efficacy of Trauma-Focused Cognitive Behavioral Therapy with Sexually Exploited, War Affected Adolescent Girls in the Democratic Republic of Congo. This study seeks to fill this gap by designing, implementing and testing such an intervention using both an intervention and waiting list control group.


Options:
A: Intervention Type: BEHAVIORAL; Name: Early psychological intervention; Assigned to Arm(s): N/A
B: Arm Label: IPT arm; Type: EXPERIMENTAL; Interventions: Behavioral: interpersonal psychotherapy for groups | Arm Label: CP arm; Type: EXPERIMENTAL; Interventions: Behavioral: creative play therapy | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: interpersonal psychotherapy for groups; Assigned to Arm(s): IPT arm | Intervention Type: BEHAVIORAL; Name: creative play therapy; Assigned to Arm(s): CP arm
C: Arm Label: NET; Type: EXPERIMENTAL; Interventions: Behavioral: Narrative Exposure Therapy | Arm Label: AC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Academic Counseling | Arm Label: WL; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Narrative Exposure Therapy; Assigned to Arm(s): NET | Intervention Type: BEHAVIORAL; Name: Academic Counseling; Assigned to Arm(s): AC
D: Arm Label: Trauma-Focused Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Trauma-Focused Cognitive Behavioral Therapy | Arm Label: Waiting List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trauma-Focused Cognitive Behavioral Therapy; Assigned to Arm(s): Trauma-Focused Cognitive Behavioral Therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is Trauma-Focused Cognitive Behavioral Therapy Effective in Reducing Post-traumatic Stress and Psychosocial Distress Among Sexually Exploited, War-affected Girls in the Democratic Republic of Congo.
Brief Summary: To date, no RCT has examined the efficacy of Trauma-Focused Cognitive Behavioral Therapy with Sexually Exploited, War Affected Adolescent Girls in the Democratic Republic of Congo. This study seeks to fill this gap by designing, implementing and testing such an intervention using both an intervention and waiting list control group.


Options:
A: Arm Label: E-CAU with Group Problem Management Plus (PM+); Type: EXPERIMENTAL; Interventions: Behavioral: Problem Management Plus (PM+) | Arm Label: Enhanced care as usual (E-CAU) only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Problem Management Plus (PM+); Assigned to Arm(s): E-CAU with Group Problem Management Plus (PM+)
B: Arm Label: THPP-I; Type: EXPERIMENTAL; Interventions: Behavioral: THPP-I, Behavioral: EUC | Arm Label: Enhanced usual care (EUC); Type: OTHER; Interventions: Behavioral: EUC | Intervention Type: BEHAVIORAL; Name: THPP-I; Assigned to Arm(s): THPP-I | Intervention Type: BEHAVIORAL; Name: EUC; Assigned to Arm(s): Enhanced usual care (EUC), THPP-I
C: Arm Label: Control - VSLA; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control - Mental Health; Type: OTHER; Interventions: Behavioral: Treatment as usual | Arm Label: Voluntary Savings/Loans Assoc; Type: EXPERIMENTAL; Interventions: Behavioral: Voluntary Savings/Loans Assoc | Arm Label: Cognitive Processing Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Control - Mental Health | Intervention Type: BEHAVIORAL; Name: Voluntary Savings/Loans Assoc; Assigned to Arm(s): Voluntary Savings/Loans Assoc | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): Cognitive Processing Therapy
D: Arm Label: Trauma-Focused Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Trauma-Focused Cognitive Behavioral Therapy | Arm Label: Waiting List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trauma-Focused Cognitive Behavioral Therapy; Assigned to Arm(s): Trauma-Focused Cognitive Behavioral Therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE)
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: Etanercept 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept 50 mg
B: Arm Label: KHK4827 70mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 140mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 210mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: KHK4827; Assigned to Arm(s): KHK4827 140mg SC, KHK4827 210mg SC, KHK4827 70mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC
C: Arm Label: CNTO 1959 (5 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (5 mg) | Arm Label: CNTO 1959 (15 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (15 mg) | Arm Label: CNTO 1959 (50 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (50 mg) | Arm Label: CNTO 1959 (100 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (100 mg) | Arm Label: CNTO 1959 (200 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (200 mg) | Arm Label: Adalimumab (approved psoriasis dosing); Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Arm Label: Placebo to CNTO 1959 (100 mg); Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1959 (100 mg), Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1959 (5 mg); Assigned to Arm(s): CNTO 1959 (5 mg) | Intervention Type: DRUG; Name: CNTO 1959 (15 mg); Assigned to Arm(s): CNTO 1959 (15 mg) | Intervention Type: DRUG; Name: CNTO 1959 (50 mg); Assigned to Arm(s): CNTO 1959 (50 mg) | Intervention Type: DRUG; Name: CNTO 1959 (100 mg); Assigned to Arm(s): CNTO 1959 (100 mg), Placebo to CNTO 1959 (100 mg) | Intervention Type: DRUG; Name: CNTO 1959 (200 mg); Assigned to Arm(s): CNTO 1959 (200 mg) | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab (approved psoriasis dosing) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo to CNTO 1959 (100 mg)
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Communication Skills Intervention to Promote Transition Into Survivorship
Brief Summary: The purpose of this study is to improve the communication skills of physicians who transition lymphoma cancer patients from the end of treatment to survivorship.


Options:
A: Arm Label: initial survivorship planning consultation; Type: N/A; Interventions: N/A | Arm Label: initial wellness rehabilitation consultation; Type: N/A; Interventions: N/A
B: Arm Label: Shared decision-making program; Type: EXPERIMENTAL; Interventions: Other: Shared decision-making program | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Shared decision-making program; Assigned to Arm(s): Shared decision-making program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Communication training and coaching | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Communication training and coaching; Assigned to Arm(s): Intervention
D: Arm Label: Nueva Vida Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nueva Vida Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nueva Vida Intervention; Assigned to Arm(s): Nueva Vida Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Trial of a Novel Catheter Lock Solution For Adjunctive Treatment of Hemodialysis Catheter-Associated Bacteremia.
Brief Summary: Aim: To conduct a randomized, double-blinded, controlled phase II trial to investigate the use of a catheter lock solution consisting of N-acetylcysteine, tigecycline and heparin, in addition to systemic antibiotics, for the treatment of hemodialysis catheter-associated bacteremia via a catheter-salvage strategy.

The investigators plan to randomize 102 patients with hemodialysis catheter-associated bacteremia to one of two treatment arms. All patients will receive systemic antibiotics for treatment of their infection. Additionally, patients randomized to the interventional arm will also receive a catheter lock solution consisting of N-acetylcysteine, tigecycline and heparin for 2 weeks with the aim of salvaging the catheter. The control arm will receive only an anticoagulant solution as a catheter lock which is standard of care - this can be either heparin or citrate (depending on what agent is standard of care for a particular patient). The main outcome of interest is successful treatment which is defined as a resolution of the current episode of bacteremia as well as lack of recurrent bacteremia within 90 days of follow-up.


Options:
A: Intervention Type: DRUG; Name: Cefazolin IV; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Linezolid IV; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vancomycin (IV); Assigned to Arm(s): N/A
B: Arm Label: group A; Type: ACTIVE_COMPARATOR; Interventions: Device: catheter replacement | Arm Label: group B; Type: ACTIVE_COMPARATOR; Interventions: Device: catheter replacement | Intervention Type: DEVICE; Name: catheter replacement; Assigned to Arm(s): group A, group B
C: Arm Label: NAC/Tigecycline/Heparin combination lock solution; Type: EXPERIMENTAL; Interventions: Drug: NAC/Tigecycline/Heparin combination lock solution | Arm Label: Standard anticoagulant (heparin or citrate); Type: PLACEBO_COMPARATOR; Interventions: Drug: Standard anticoagulant (Heparin or Citrate) | Intervention Type: DRUG; Name: NAC/Tigecycline/Heparin combination lock solution; Assigned to Arm(s): NAC/Tigecycline/Heparin combination lock solution | Intervention Type: DRUG; Name: Standard anticoagulant (Heparin or Citrate); Assigned to Arm(s): Standard anticoagulant (heparin or citrate)
D: Arm Label: Antibiotic Lock Solution; Type: EXPERIMENTAL; Interventions: Drug: tigecycline, N-acetylcysteine, heparin combination | Arm Label: Guide-wire Exchange; Type: ACTIVE_COMPARATOR; Interventions: Device: guide-wire exchange | Intervention Type: DRUG; Name: tigecycline, N-acetylcysteine, heparin combination; Assigned to Arm(s): Antibiotic Lock Solution | Intervention Type: DEVICE; Name: guide-wire exchange; Assigned to Arm(s): Guide-wire Exchange

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efectiveness of a Cognitive Behavioral Intervention in Patients With Symptoms Somatization, as Measure Quality of Life, Front the Clinical Practice Usual Action in Primary Health Care. A Controlled Clinical Trial With Parallel Groups
Brief Summary: The purpose of this study is to evaluate the efectiveness of a behavioral cognitive grupal intervention (BCI) in patients with somatization symptoms which has an effect on the perceived quality of life front conventional intervention.


Options:
A: Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Recommendation of care (letter to general practitioner [GP]); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducational counseling | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Relaxation response training | Intervention Type: BEHAVIORAL; Name: Relaxation response training; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Psychoeducational counseling; Assigned to Arm(s): 1
C: Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Experimental Group
D: Arm Label: Psychosocial Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Psychosocial Counseling | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Psychosocial Counseling; Assigned to Arm(s): Psychosocial Counseling | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exposure Therapy in Chronic Low Back Pain Patients
Brief Summary: Chronic low back pain often results in psychosocial and physical disability. A subgroup of these patients shows fear of (re)injury and avoidance behaviour leading to higher disability. The purpose of this study is to determine whether exposure in vivo is more effective in the treatment of fear avoidant chronic back pain patients than psychological treatment as usual (cognitive behavioural psychotherapy).


Options:
A: Arm Label: Integrative Medicine Group Visits; Type: EXPERIMENTAL; Interventions: Behavioral: Integrative Medicine Group Visits | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrative Medicine Group Visits; Assigned to Arm(s): Integrative Medicine Group Visits
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychoeducative program in fibromyalgic patients | Intervention Type: BEHAVIORAL; Name: Psychoeducative program in fibromyalgic patients; Assigned to Arm(s): 1
C: Arm Label: Prescribed physical activity; Type: OTHER; Interventions: Other: Prescribed physical activity | Arm Label: Neck specific training; Type: OTHER; Interventions: Other: Neck specific training | Intervention Type: OTHER; Name: Prescribed physical activity; Assigned to Arm(s): Prescribed physical activity | Intervention Type: OTHER; Name: Neck specific training; Assigned to Arm(s): Neck specific training
D: Arm Label: A Exposure long; Type: EXPERIMENTAL; Interventions: Behavioral: Exposure in vivo | Arm Label: B Exposure short; Type: EXPERIMENTAL; Interventions: Behavioral: Exposure in vivo | Arm Label: C Cognitive behavioural psychotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioural Psychotherapy | Intervention Type: BEHAVIORAL; Name: Exposure in vivo; Assigned to Arm(s): A Exposure long, B Exposure short | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Psychotherapy; Assigned to Arm(s): C Cognitive behavioural psychotherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects With Systemic Lupus Erythematosus (SLE)
Brief Summary: The purpose of this study is to evaluate the efficacy, safety and tolerability of belimumab administered subcutaneously (SC) to adult subjects with Systemic Lupus Erythematosus (SLE).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Arm Label: Belimumab 4 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Arm Label: Beimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Arm Label: Belimumab 20 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Belimumab 4 mg/kg | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Beimumab 10 mg/kg | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Belimumab 20 mg/kg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg
C: Arm Label: Placebo plus standard therapy; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Standard therapy | Arm Label: Belimumab 200 mg SC plus standard therapy; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 200 mg SC, Drug: Standard therapy | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo plus standard therapy | Intervention Type: BIOLOGICAL; Name: Belimumab 200 mg SC; Assigned to Arm(s): Belimumab 200 mg SC plus standard therapy | Intervention Type: DRUG; Name: Standard therapy; Assigned to Arm(s): Belimumab 200 mg SC plus standard therapy, Placebo plus standard therapy
D: Arm Label: Belimumab Q2WKS; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 100 mg SC | Arm Label: Belimumab 3X/WK; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 100 mg SC | Intervention Type: DRUG; Name: Belimumab 100 mg SC; Assigned to Arm(s): Belimumab Q2WKS | Intervention Type: DRUG; Name: Belimumab 100 mg SC; Assigned to Arm(s): Belimumab 3X/WK

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Randomized, Placebo-Controlled, Two-Period, Fixed Sequence Study To Evaluate The Effect Of CP-690,550 On Measured Glomerular Filtration Rate In Patients With Active Rheumatoid Arthritis
Brief Summary: The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).


Options:
A: Arm Label: Certolizumab pegol 400 mg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Certolizumab pegol 200 mg and placebo; Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 400 mg and placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo, Certolizumab pegol 400 mg and placebo, Placebo
B: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate placebo | Arm Label: Adalimumab + methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate | Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Biological: Adalimumab placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Adalimumab + methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Adalimumab + methotrexate, Methotrexate | Intervention Type: BIOLOGICAL; Name: Adalimumab placebo; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Methotrexate placebo; Assigned to Arm(s): Adalimumab
C: Arm Label: Tocilizumab 8 mg/kg + DMARDs; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab, Drug: Permitted DMARDs | Arm Label: Placebo + DMARDs; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Permitted DMARDs | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Tocilizumab 8 mg/kg + DMARDs | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + DMARDs | Intervention Type: DRUG; Name: Permitted DMARDs; Assigned to Arm(s): Placebo + DMARDs, Tocilizumab 8 mg/kg + DMARDs
D: Arm Label: Sequence 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: CP-690,550 or Placebo | Arm Label: Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550 or Placebo; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Randomized, Placebo-Controlled, Two-Period, Fixed Sequence Study To Evaluate The Effect Of CP-690,550 On Measured Glomerular Filtration Rate In Patients With Active Rheumatoid Arthritis
Brief Summary: The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).


Options:
A: Arm Label: Active 5 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 5 mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2
B: Arm Label: Sequence 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: CP-690,550 or Placebo | Arm Label: Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550 or Placebo; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 2
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: MTX | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Infliximab, Drug: MTX | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Infliximab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1

Answer: B